J&J Unit Hit With Antitrust Suit Over 'Sham' Zytiga Patent
The city of Baltimore has filed a proposed class action antitrust case against the Johnson & Johnson unit that makes the prostate cancer drug Zytiga, alleging the company filed "sham" lawsuits...To view the full article, register now.
Already a subscriber? Click here to view full article